(Rac)-JBJ-04-125-02
CAS No. 2140807-05-0
(Rac)-JBJ-04-125-02 ( —— )
Catalog No. M23974 CAS No. 2140807-05-0
JBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 205 | In Stock |
|
10MG | 335 | In Stock |
|
25MG | 566 | In Stock |
|
50MG | 806 | In Stock |
|
100MG | 1098 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(Rac)-JBJ-04-125-02
-
NoteResearch use only, not for human use.
-
Brief DescriptionJBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.
-
DescriptionJBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR (L858R/T790M )
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2140807-05-0
-
Formula Weight543.6
-
Molecular FormulaC29H26FN5O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO:240mg/mL (441.5 mM);Water:Insoluble
-
SMILESC1CN(CCN1)C2=CC=C(C=C2)C3=CC4=C(CN(C4=O)C(C5=C(C=CC(=C5)F)O)C(=O)NC6=NC=CS6)C=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
molnova catalog
related products
-
Nimotuzumab
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
-
AZD-9291
A potent, selective, third-generation irreversible inhibitor of mutant EGFR with IC50s of 1/12/5 nM for L858R-T790M/L858R/L861Q respectively.
-
AZ7550 hydrochloride
AZ7550 hydrochloride, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).